Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

Completed · Phase 3 · Has a placebo group

Conditions studied: Allergic Rhinitis

In brief

The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration

Key facts

Study ID

NCT00599872

Run by

Greer Laboratories

People needed

430

Starts

2008-03-01

Expected to finish

2008-12-01

Last updated by the study team

2015-01-14

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult ragweed-sensitive Subjects with allergic rhinoconjunctivitis with or without asthma during ragweed pollen season.
• Subjects must be 18 to 50 years of age.
• Test Subjects will have a history of moderate to severe isolated or unseasonal allergic rhinoconjunctivitis with or without mild intermittent asthma symptoms attributable to ragweed pollen for a minimum of 2 years before study entry.
• Subjects with or with out a history of asthma will possess FEV1 and PEF greater than or equal to 80% predicted at the beginning of the study established by spirometry and defined by the Knudson predicted set.
• Sensitivity to the relevant allergen will be documented by a positive skin prick test result performed along with negative (saline) and positive (histamine) control skin tests. A positive test will be defined as the skin reaction having the longest wheal diameter of 5mm or greater or the longest erythema diameter of 10 mm or greater at 15-20 minutes after application.
• All female Subjects of child-bearing potential will be required to provide a urine sample for pregnancy testing that must be negative before being allowed to participate in the study.
• Subjects must be planning to remain in the study area during the trial (see exclusion criteria # 14).
• Subjects must be trained on the proper use of the EpiPen, and sign the EpiPenTraining Form before being allowed to enroll in the study.
• Subjects must be mentally and physically capable of self-administering oral drug.

You may not qualify if…

• Subjects having a history of anaphylaxis or history consistent with persistent asthma
• Subjects taking antihistamines or nasal steroids medications greater than twice a week in the months of January and/or February.
• Subjects with chronic sinusitis unstable angina, significant arrhythmia, uncontrolled hypertension, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the test drug or pose additional risk to the Subject.
• Subjects having perennial or structurally related rhinitis or rhinitis medicamentosa (from excessive use of nasal decongestants) that will interfere with the evaluation of symptoms due to ragweed allergy.
• Subjects with an FEV1 or PEF less than 80% predicted (moderate persistent asthma) with or without controller medication.
• Subjects who have received an experimental drug in the 30 days prior to admission into this study or who plan to use an experimental drug during the study.
• Subjects who have received Anti-IgE medications (Xolair) or similar compounds in the last 12 months.
• Subjects who have received ragweed allergen immunotherapy in the last 3 years prior to admission into this study.
• Subjects who are current users of inhaled, oral, intramuscular, intravenous corticosteroids, tricyclic antidepressants, beta blockers, or MAO inhibitors.
• Subjects using beta-agonist more than twice a month unless being taken prior to exercise.
• Subjects using medications that could induce adverse gastrointestinal reactions during the study. Subjects using such medications must prove stable with no side effects for at least 3 months prior to enrollment.
• Subjects refusing to sign the EpiPen Training Form will be excluded from the study.
• Pregnant or breast feeding females.
• Subjects who plan to leave the study area for more than 2 consecutive weeks during the study.
• Subjects with a positive skin prick test to cat and/or dog, and own the pet(s) to which they are allergic.
• Subjects who sleep during the day due to working third shift.
• Subjects unable to achieve dose #2 or higher during preliminary dosing will be excluded.

Where it is running

• Toledo Center for Clinical Research — Sylvania, Ohio, United States
• Oklahoma Allergy & Asthma Clinic, PC — Oklahoma City, Oklahoma, United States
• Allergy, Asthma and Clinical Research Center — Oklahoma City, Oklahoma, United States
• Valley Clinical Research Center — Bethlehem, Pennsylvania, United States
• Allergy and Asthma Specialists, PC — Blue Bell, Pennsylvania, United States
• Allegheny General Hospital — Pittsburgh, Pennsylvania, United States
• Asthma and Allergy Research Associates — Upland, Pennsylvania, United States
• Vanderbilt ASAP Research — Nashville, Tennessee, United States
• Pharmaceutical Research & Consulting, Inc — Dallas, Texas, United States
• Allergy, Asthma and Sinus Center, SC — Greenfield, Wisconsin, United States
• University of Wisconsin — Madison, Wisconsin, United States
• Aurora Advanced Healthcare, Inc — Milwaukee, Wisconsin, United States
• Sneeze, Wheeze, & Itch Associates — Normal, Illinois, United States
• Welborn Clinic — Evansville, Indiana, United States
• Iowa Clinical Research Corporation — Iowa City, Iowa, United States
• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• College Park Family Care Center — Overland Park, Kansas, United States
• Kansas City Allergy and Asthma — Overland Park, Kansas, United States
• Family Allergy and Asthma Respiratory Institute — Louisville, Kentucky, United States
• Clinical Research Institute — Minneapolis, Minnesota, United States
• Clinical Research of the Ozarks — Rolla, Missouri, United States
• Midwest Clinical Research, LLC — St Louis, Missouri, United States
• Asthma, Immunology and Allergy Association, LLC — Lincoln, Nebraska, United States
• Midwest Allergy and Asthma Clinic, PA — Omaha, Nebraska, United States
• Creighton University — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.